CLINICAL EXPERIENCE WITH MONTHLY NORETHISTERONE ENANTHATE-ESTRADIOL VALERATE
Objective: In this study we aimed to investigate the reasons of preference, sociodemographic features, side effects encountered during use and reasons of discontinuation in women using monthly norethisterone enanthate (NET-EN) /estradiol valerate (EV) injections as a contraceptive method.
Methods: A standardized questionnaire was used to evaluate 135 women using NET-EN/EV. The questionnaire consisted of 29 closed-ended questions. The data collected was analyzed using the x2 test using SPSS-9.0 for Windows statistics programme.
Results: The most frequent reason for preferring this method was reliability (47%). The most common bleeding problem was spotting (27%). Spotting was also the most frequent complaint and side effect (13%). The discontinuation rate for NET-EN/EV injections was 41% whereas the continuation rate was 59%. The most common reason for discontinuation was planning to concieve (39%). There was a positive correlation between spotting and discontinuing the method (p<0, 05). The discontinuers most frequently chose IUD’s (7%) and combined oral contraceptive pills (3%) as new contraceptive methods. Sixty-one percent of the discontinuers did not want to concieve; however, 6.7% of these women had not chosen a new method of contraception.
Conclusion: NET-EN/EV has been available in Turkey for the last 9 years. Women using monthly NET-EN/EV injections as a contraceptive should be followed closely and counseled thoroughly in order to increase continuation rates